Focal Medical, Inc.

Focal Medical, Inc. is a biopharmaceutical company founded in 2014 and operating in the United States. The company is focused on developing targeted therapeutic products utilizing innovative local drug-delivery technology platforms. Its lead product delivers gemcitabine, an FDA-approved chemotherapeutic, directly to the pancreas to treat pancreatic cancer. This delivery is achieved through non-circulatory pathways, offering a promising approach to cancer treatment. The latest milestone in Focal Medical's journey is the $11.60M Series A investment on 03 September 2020. This investment round was backed by notable investors including Khosla Ventures and Spectrum Financial, highlighting the industry's confidence in the company's innovative approach. Focal Medical's commitment to addressing critical unmet medical needs, particularly in the field of cancer treatment, positions it as a compelling investment opportunity. The company's focus on targeted therapeutic products and its ability to attract significant investment support from reputable venture capital firms can be seen as a testament to its potential for growth and innovation in the biopharma and biotechnology industries.